Приказ основних података о документу
Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis
dc.creator | Jančić, Ivan | |
dc.creator | Sefik-Bukilica, Mirjana | |
dc.creator | Živojinović, Slađana | |
dc.creator | Damjanov, Nemanja | |
dc.creator | Spasovski, Vesna | |
dc.creator | Kotur, Nikola | |
dc.creator | Klaassen, Kristel | |
dc.creator | Pavlović, Sonja | |
dc.creator | Bufan, Biljana | |
dc.creator | Arsenović-Ranin, Nevena | |
dc.date.accessioned | 2019-09-02T11:45:02Z | |
dc.date.available | 2019-09-02T11:45:02Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1452-8258 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/2331 | |
dc.description.abstract | Background: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy. | en |
dc.publisher | Društvo medicinskih biohemičara Srbije, Beograd i Versita | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175050/RS// | |
dc.rights | openAccess | |
dc.source | Journal of Medical Biochemistry | |
dc.title | Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Спасовски, Весна; Дамјанов, Немања; Буфан, Биљана; Јанчић, Иван; Сефик-Букилица, Мирјана; Клаассен, Кристел; Павловић, Соња; Котур, Никола; Живојиновић, Слађана; Aрсеновић-Ранин, Невена; | |
dc.citation.volume | 34 | |
dc.citation.issue | 4 | |
dc.citation.spage | 414 | |
dc.citation.epage | 421 | |
dc.citation.other | 34(4): 414-421 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000363003400004 | |
dc.identifier.doi | 10.2478/jomb-2014-0060 | |
dc.identifier.pmid | 28356850 | |
dc.identifier.scopus | 2-s2.0-84942865195 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1042/2329.pdf | |
dc.type.version | publishedVersion |